

**Caplin Point Laboratories Limited** 

Regd. office: Ashvich Tower, 3rd Floor,

No.3, Developed Plots Industrial Estate, Perungudi, Chennai – 600096.

Phone: +91 44 24968000 / +91 80127 72888 / +91 44 71148000

E-mail: info@caplinpoint.net / Website: www.caplinpoint.net

CIN: L24231TN1990PLC019053

29.09.2020

BSE Limited
Department of Corporate Relationship
1st Floor, New Trade Ring, Rotunda Building,
Phiroze jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001.
Scrip Code: 524742

By BSE Listing

National Stock Exchange of India Ltd., Department of Corporate Services, Exchange Plaza, 5<sup>th</sup> Floor, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051. Scrip Code: CAPLIPOINT

By NEAPS

Dear Sirs,

SUB:COMPLIANCE UNDER REGULATION 30 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015- SUMMARY OF PROCEEDINGS OF 29<sup>TH</sup> ANNUAL GENERAL MEETING

The 29<sup>th</sup> Annual General Meeting of the Company was held on Monday, September 28, 2020 at 10:00 AM through Video Conferencing pursuant to MCA circular No.14/2020 dated April 08, 2020, Circular No.17/2020 dated April 13, 2020 and Securities and Exchange Board of India vide its Circular dated May 12, 2020.


Mr Vinod Kumar S, Company Secretary, welcomed the members present and introduced the Directors of the Company who are participating from various locations and further, he briefed about the remote e-voting details and informed that those members who are present at the virtual AGM and who did not participate in the remote e-voting can cast their votes through e-voting platform provided by NSDL any time during the meeting and e-voting platform will be kept open for 15 minutes after the conclusion of the meeting.

Dr Sridhar Ganesan, Manager Director welcomed the Directors, invitees and members to the meeting and requested Mr CC Paarthipan, Chairman to Chair the Meeting.


Mr C C Paarthipan, Chairman occupied the Chair and welcomed the members present. Chairman called the meeting to order as the requisite quorum was present.

Register of Directors and Key Managerial Personnel and their shareholding maintained under Section 170 read with Section 171 of the Companies Act, 2013 were made available for inspection electronically till the conclusion of the meeting through separate link provided by NSDL.

## Caplin Point Laboratories Limited



No.3, Developed Plots Industrial Estate, Perungudi, Chennai - 600096. Phone: +91 44 24968000 / +91 80127 72888 / +91 44 71148000 E-mail: info@caplinpoint.net / Website: www.caplinpoint.net



Chairman thereafter addressed the members present. He started thanking the Covid Warriors and all the Employees in India and with Overseas Subsidiaries who stood by the Company against odds. He mentioned that the Company has been able to strategies its business model to suit the current situation. This has resulted in increased Cash accrual. He further explained about the Company's future plans including expansion into larger territories of Latin American markets and entry in US markets. He also briefed about the back ward integration plans of the Company.

CAPLIN POIN

Chairman then directed Dr Sridhar Ganesan to make his presentation, Dr Sridhar made presentation about the Company's financial performance and product portfolio.

Mr Vivek, COO briefed about the product launches in the US Market and about the capacity expansion in US FDA approved facility. He also briefed on medium term strategy for US and other Regulated Markets.

Further, Mr R Viswanthan and Dr K C John, Directors delivered their speeches.

Chairman then mentioned that the Annual Report together with Notice was circulated through email and with the consent of the members present it was taken as read. He further mentioned that Statutory Auditors Report and Secretarial report stands unmodified and the same have been taken as read.

Chairman then requested the speaker shareholders who have registered themselves as speakers to raise queries and two members raised queries about the operational and financial performance of the Company and their queries were answered to their satisfaction.

The Following businesses were transacted at the Annual General Meeting:

| S.No   | Nature of Business  |
|--------|---|
| Ordina | ry Business   |
| 01     | Adoption of financial statements for the year ended March 31,2020                     |
| 02     | Declaration of Final dividend and ratification of Interim dividend for the FY 2019-20 |
| 03     | Re-appointment of Dr DP Mishra who is liable to retire by rotation                    |
| Specia | Business  |
| 04     | Re-appointment of Dr Sridhar Ganesan as Managing Director                             |
| 05     | Appointment of Dr C K Gariyali as an Independent Director                             |
| 06     | Approval of related party transactions.   |
|        |   |

Chairman thanked the members who participated in the meeting and declared the meeting as closed. Mr D P Mishra delivered vote of thanks.

Meeting concluded at 11:00 AM.

Thanking You,

Yours Faithfully,

For Caplin Point Laboratories Limited